XORTX Therapeutics Files October 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K, foreign-private-issuer
TL;DR
XORTX filed its October 6-K, confirming 20-F annual report status. CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 9, 2024, to report its activities for the month of October 2024. The filing indicates the company is a foreign private issuer and will file its annual reports under Form 20-F. The report was signed by CEO Allen Davidoff.
Why It Matters
This filing provides an update on XORTX Therapeutics' ongoing operations and regulatory compliance as a foreign private issuer. Investors can use this to track company disclosures.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and providing a signature, with no new material financial or operational information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- October 9, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2024.
Which form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed this Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The filing was signed by Allen Davidoff, Chief Executive Officer of XORTX Therapeutics Inc.
What is the filing date of this report?
The filing date of this report is October 9, 2024.
What is the company's primary business classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-09 10:04:20
Filing Documents
- f6k_100924.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-005570.txt ( ) — 15KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 9, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated October 9, 2024